S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

GILD Gilead Sciences Inc

90.64

-0.36 (-0.40%)

Pre Market

Last Updated: 22:41:22

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Gilead Sciences Charts.

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Gilead Sciences Charts.

Gilead Sciences Inc News

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Sunday 12 January 2025 (4 days ago) • Business Wire

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Saturday 11 January 2025 (5 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 4 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Saturday 4 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 24 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Tuesday 24 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Gilead Sciences to Present at Upcoming Investor Conference
Saturday 21 December 2024 (4 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Friday 20 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 20 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 18 December 2024 (4 weeks ago) • Edgar (US Regulatory)

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Wednesday 18 December 2024 (4 weeks ago) • Business Wire

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Tuesday 17 December 2024 (4 weeks ago) • Business Wire

More Gilead Sciences Inc News Articles

Invesco QQQ Trust Series 1

S&P ASX 300 Metals and M...

Newcrest Mining

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions